Skip to main content

Kracov, Habtemariam Quoted in Bloomberg Law on FDA Reclassification of Certain Drugs to Devices

January 13, 2022

Life Sciences and Healthcare Regulatory partners Dan Kracov and Abeba Habtemariam were quoted in a recent article from Bloomberg Law, “Drug or Device? Manufacturers See Burden in FDA Reclassifying.” The article discusses the FDA’s potential reclassification of certain drugs as medical devices. Kracov, co-chair of the firm's Life Sciences and Healthcare Regulatory practice, comments on the industry reaction to the agency’s decision. Habtemariam notes a recent court ruling on drug and device definitions, reflecting on the whether the FDA will establish new classifications for those categories of agents.

» Read the full article (subscription required).